The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial
Abstract
PURPOSE: The identification of clinically insignificant prostate cancer could help avoid overtreatment. Current criteria for insignificant prostate cancer use a tumor volume threshold of less than 0.5 ml for the index tumor. In this study we reassess this tumor volume threshold for clinically insignificant prostate cancer using an independent data set. MATERIALS AND METHODS: The rate of insignificant prostate cancer was calculated by modeling lifetime risk estimates of prostate cancer diagnosis in screened and nonscreened participants in a randomized prostate cancer screening trial. Using lifetime risk estimates 50.8% of screen detected prostate cancer was calculated to be clinically insignificant and the 49.2% largest tumor volume of 325 prostatectomy specimens was used to determine the threshold tumor volume for insignificant prostate cancer. Because stage and grade represent the strongest determinants of cancer aggressiveness, we also calculated the tumor volume threshold for insignificant cancer after the selection of patients with organ confined prostate cancer without Gleason pattern 4/5. The analyses were performed for total tumor volume and for index tumor volume. RESULTS: The minimum threshold tumor volume of the index tumor and total tumor was 0.55 and 0.70 ml, respectively. After accounting for tumor stage and grade we obtained a threshold volume for the index tumor and total tumor of 1.3 and 2.5 ml, respectively. CONCLUSIONS: We confirmed the original value of the index tumor volume threshold of 0.5 ml for insignificant prostate cancer, and we demonstrated that clinically insignificant prostate cancer may include index Gleason score 6, pT2 tumors with volumes up to at least 1.3 ml. These results suggest a reconsideration of current methods and nomograms used for pretreatment risk assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Han, M., Partin, A. W., Pound, C. R., Epstein, J. I., & Walsh, P. C. (2001) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70163-4 · Cited by 1,028
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., & de Koning, H. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp001 · Cited by 796
PATTERNS OF PROGRESSION IN PROSTATE CANCER
Mcneal, J., Kindrachuk, R., Freiha, F., Bostwick, D., Redwine, E., & Stamey, T. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90715-4 · Cited by 582
Walsh, P. C., DeWeese, T. L., & Eisenberger, M. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp0706784 · Cited by 321
Overdiagnosis and overtreatment of early detected prostate cancer
Bangma, C. H., Roemeling, S., & Schröder, F. H. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0145-z · Cited by 169
Self-citation794: Is Tumor Volume an Independent Prognostic Factor in Clinically Localized Prostate Cancer?
Kikuchi, E., Ohori, M., Wheeler, T. M., Slawin, K. M., & Scardino, P. T. (2004) · The Journal of Urology · doi:10.1016/s0022-5347(18)38043-1 · Cited by 121
Sengupta, S., Blute, M. L., Bagniewski, S. M., Inman, B. A., Leibovich, B. C., Slezak, J. M., Myers, R. P., & Zincke, H. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07270.x · Cited by 36
Cited by
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Artificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Self-citationBarentsz, J. O., Weinreb, J. C., Verma, S., Thoeny, H. C., Tempany, C. M., Shtern, F., Padhani, A. R., Margolis, D., Macura, K. J., Haider, M. A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.038 · Cited by 547
Metadata
- Authors
- Wolters, T., Roobol, M. J., van Leeuwen, P. J., van den Bergh, R. C. N., Hoedemaeker, R. F., van Leenders, G. J. L. H., Schröder, F. H., & van der Kwast, T. H.
- Venue
- Journal of Urology
- Published
- 2011-01
- Volume
- 185
- Issue
- 1
- Pages
- 121-125
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2131241259
- Cited by
- 280
- References
- 10
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. https://app.cochat.ai/papers/10.1016/j.juro.2010.08.082
- The paper
- Wolters, T., Roobol, M. J., van Leeuwen, P. J., van den Bergh, R. C. N., Hoedemaeker, R. F., van Leenders, G. J. L. H., Schröder, F. H., & van der Kwast, T. H. (2011). A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. Journal of Urology. https://doi.org/10.1016/j.juro.2010.08.082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.